Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

4
ESMO-MCBS v1.1
Scorecard version: 1

Indication details

Tumour Type
Thoracic Malignancies
Tumour Sub-type
Non-small-cell Lung Cancer
Tumour Sub-Group
ALK+
Tumour stage
Advanced
Control Arm
Chemotherapy (pemetrexed or docetaxel)
Treatment Setting
ALK-positive advanced NSCLC previously treated with crizotinib
Trial Name
ALUR

Primary Outcome(s)

Primary Outcome(s)
PFS (investigator assessment)
Form(s)
Form 2b

Outcome Data

PFS Control
1.4 months
PFS Gain
8.2 months
PFS HR
0.15 (0.08-0.29)
Toxicity Comment
Improved toxicity profile

Final Score (after adjustments)

Preliminary non-curative score
3
Toxicity adjustment
1+
Final non-curative Score
4
Release date
23.07.2021

ChT; chemotherapy; DFS, disease-free survival; DoR, duration of response; EFS, event-free survival; FFS, failure-free survival; HR, hazard ratio; iDFS, invasive disease-free survival; ITT, intention to treat; MFS, metastasis-free survival; ORR, overall response rate; OS, overall survival; pCR, pathologic complete response/remission; PE, point estimate; PFS, progression-free survival; QoL, quality of life; RFS, relapse-free survival; RR, response rate; SD, stable disease; SSA, somatostatin analogue; SSTR, somatostatin receptor; TKI, tyrosine kinase inhibitor, TTP, time to progression

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings